Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Abstract
References
LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei. Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 199-202. DOI: 10.12290/xhyxzz.2021-0715
Citation: LEI Lei, DU Tao, OU Xia, ZHU Yan, ZHANG Yu, ZHANG Wei. Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 199-202. DOI: 10.12290/xhyxzz.2021-0715
shu

Treatment of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms by Radionuclide Therapy: Practice and Experience

  • 1.

    Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

  • 2.

    Department of Nuclear Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610072, China

More Information
  • Corresponding author:

    ZHANG Wei, E-mail: zhangwscd@163.com

  • Received Date: October 27, 2021
  • Accepted Date: December 28, 2021
  • Available Online: December 29, 2021
  • Issue Publish Date: March 29, 2022
    Graphical Abstract
    • Abstract
  • Peptide receptor radionuclide therapy (PRRT) is one of the advanced therapies for neuroendocrine neoplasms (NENs), which can relieve the symptoms and improve the quality of life of patients with NENs with good tolerance to the treatment.However, since this treatment method has just started in China, how to implement standardized, efficient and high-quality nursing services for patients undergoing PRRT is still worth discussing. By referring to related international guidelines and clinical nursing standards, and combining our experience in the treatment of NENs using 177Lu-DOTATATE, we proposed the key nursing points during the treatment process, and elaborated how to prevent common adverse reactions and undergo psychological intervention, in hope of the related personnel being able to provide more safe treatment and to improve nursing security.
    • FullText(HTML)
    • References (15)
  • [1]
    中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组. 胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州)[J]. 中华消化杂志, 2021, 41: 76-87.
    [2]
    Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 800-816. DOI: 10.1007/s00259-012-2330-6
    [3]
    刘会攀, 陈跃. 放射性核素诊治神经内分泌肿瘤的应用进展[J]. 中华核医学与分子影像杂志, 2019, 39: 564-567. DOI: 10.3760/cma.j.issn.2095-2848.2019.09.015
    [4]
    Feijtel D, de Jong M, Nonnekens J. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward[J]. Curr Top Med Chem, 2020, 20: 2959-2969. DOI: 10.2174/1568026620666200226104652
    [5]
    Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2014, 55: 183-190. DOI: 10.2967/jnumed.113.125336
    [6]
    Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. DOI: 10.1056/NEJMoa1607427
    [7]
    Nicolini S, Severi S, Ianniello A, et al. Investigation of receptor radionuclide therapy with (177)Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 923-930. DOI: 10.1007/s00259-017-3925-8
    [8]
    Perren A, Couvelard A, Scoazec JY, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification[J]. Neuroendocrinology, 2017, 105: 196-200. DOI: 10.1159/000457956
    [9]
    Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours[J]. Eur Endocrinol, 2014, 10: 70-74.
    [10]
    Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors[J]. Ann Nucl Med, 2014, 28: 531-539. DOI: 10.1007/s12149-014-0843-8
    [11]
    王国慧, Lau E, Shakher R, 等. 177Lu-octreotate治疗神经内分泌胃肠胰腺肿瘤的SPECT显像研究[J]. 中华核医学杂志, 2007, 27: 313-314. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHY200705031.htm
    [12]
    Erbas B, Tuncel M. Renal Function Assessment During Peptide Receptor Radionuclide Therapy[J]. Semin Nucl Med, 2016, 46: 462-478. DOI: 10.1053/j.semnuclmed.2016.04.006
    [13]
    Shaheen S, Moradi F, Gamino G, et al. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities[J]. Curr Treat Options Oncol, 2020, 21: 25. DOI: 10.1007/s11864-020-0711-9
    [14]
    Makis W, McCann K, McEwan AJ. The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols[J]. Nucl Med Mol Imaging, 2015, 49: 223-230. DOI: 10.1007/s13139-015-0332-6
    [15]
    范素云, 柴丽, 贾彦彦, 等. 131I治疗期间甲状腺癌患者未满足的照顾需求分析[J]. 中华核医学与分子影像杂志, 2018, 38: 422-424.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (728) PDF downloads (89) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close